NYSE · UL
Unilever financials
$61.24−2.06%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.91B | $65.85B | $57.13B | $11.54B | $8.70B | $10.11B | $9.77B | $14.52B | $10.75B | $8.21B |
| Gross profit | $31.88B | $30.75B | $24.87B | $11.54B | $8.70B | $10.11B | $9.77B | $14.52B | $10.75B | $8.21B |
| Gross margin | 46.9% | 46.7% | 43.5% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $11.08B | $10.25B | $8.46B | $11.58B | $8.69B | $10.10B | $9.74B | $14.50B | $10.63B | $8.21B |
| Net income | $12.73B | $7.21B | $7.17B | $8.20B | $6.05B | $6.80B | $6.31B | $10.77B | $7.23B | $5.45B |
| Net margin | 18.7% | 10.9% | 12.6% | 71.1% | 69.5% | 67.2% | 64.6% | 74.1% | 67.2% | 66.5% |
| Diluted EPS | $5.81 | $3.24 | $3.19 | $3.61 | $2.61 | $2.90 | $2.70 | $4.50 | $2.89 | $2.15 |
| EBITDA | $14.15B | $13.39B | $10.45B | $13.67B | $10.46B | $12.56B | $11.96B | $17.04B | $13.06B | $9.75B |
| Operating cash flow | $11.23B | $11.94B | $10.42B | $7.81B | $7.97B | $11.03B | $9.10B | $8.41B | $9.45B | $7.41B |
| Free cash flow | $9.32B | $10.21B | $9.10B | $6.25B | $6.86B | $9.98B | $7.62B | $6.88B | $7.64B | $5.52B |
| Diluted shares | 2,195.3M | 2,228.5M | 2,251.0M | 2,275.4M | 2,319.6M | 2,337.6M | 2,334.8M | 2,395.4M | 2,501.3M | 2,536.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.30B | $7.70B | $4.60B | $4.33B | $3.88B | $6.76B |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $34.55B | $31.45B | $32.75B | $29.49B | $34.27B | $33.92B |
| Total assets | $94.77B | $100.07B | $83.20B | $77.82B | $85.39B | $82.40B |
| Total liabilities | $71.12B | $71.77B | $60.25B | $56.12B | $62.94B | $60.90B |
| Shareholders' equity | $23.65B | $28.30B | $22.95B | $21.70B | $22.45B | $21.50B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology